Advancing Biopharmaceutical Purification
For more than 20 years, Sepax has developed chromatography technologies that support the purification of complex biotherapeutics worldwide. From analytical characterization to commercial-scale downstream processing, our solutions help biopharmaceutical companies improve process efficiency, scalability, and purification performance.
Why Should Customers Trust Us?
Founded in 2002, Sepax has grown into a global chromatography company serving more than 5,000 customers worldwide. Sepax Bioscience represents the company's expanding focus on bioprocess chromatography and biopharmaceutical purification solutions in the United States and global markets.
Chromatography Expertise
Affinity, ion exchange, hydrophobic interaction, mixed-mode, and reverse-phase solutions across analytical and process-scale workflows.
Multiple Matrix Platforms
Agarose, polymethacrylate (PMA), polystyrene-divinylbenzene (PSDVB), and silica-based technologies designed for diverse purification challenges.
End-to-End Bioprocess Support
Supporting customers from preclinical development and IND-enabling studies through clinical manufacturing and commercial GMP production.
Global Manufacturing & Quality
Vertically integrated manufacturing with rigorous quality systems, scalable production capacity, and responsive technical support.
Advancing Chromatography Innovation Since 2002
Key milestones that shaped Sepax's growth in chromatography technology and bioprocess purification.
Foundation Era (2002–2008)
Established with a focus on chromatography materials and separation science for analytical and bioprocess applications.
Development of affinity and ion exchange chromatography resins for biopharmaceutical purification.
Global Expansion (2010–2017)
Expanded commercial operations and customer support across North America, Asia, and international markets.
Enhanced quality management and manufacturing capabilities to support clinical and commercial bioprocess applications.
Advanced Biologics Focus (2018–Present)
Development of purification solutions supporting mRNA, viral vectors, peptides, and next-generation biologics.
Provided chromatography solutions supporting accelerated vaccine and therapeutic development programs worldwide.
Expanded chromatography portfolio for complex downstream purification challenges including bispecific antibodies and ADCs.
Strengthening international partnerships, manufacturing capacity, and technical support capabilities for the growing bioprocess market.